Oncology
Engineered Bacteria as Precision Therapeutics for Cancer and Beyond
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-25-NI-09Jun 23, 2025
Announcement
Inceptor Bio and GRIT Bio Cooperate to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform
Inceptor Bio
PR-12-24-NI-142Dec 18, 2024
Cell Therapy
Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies
Beau Webber, Ph.D.
Luminary Therapeutics
PAO-08-23-CL-04Sep 05, 2023
Therapeutic Candidate
CytoDyn Takes Steps towards a Brighter Future
Cyrus Arman, Ph.D.
CytoDyn
PAO-02-23-CL-04Feb 06, 2023
CAR-T and iPSC Platform Technologies
Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR-T and Engineered iPSC Platform Technologies at the SITC 37th Annual Meeting
Umoja Biopharma
PR-M11-22-06Nov 11, 2022
Cell Therapy
Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner
Mark Shlomchik, M.D., Ph.D.
BlueSphere Bio
PAO-06-022-CL-03Jun 06, 2022
Oncology Collaboration
Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment
Tegmine Therapeutics
PR-M04-22-03Apr 06, 2022
Phase I Trial
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase I Trial at Moffitt Cancer Center
Anixa Biosciences
PR-M03-22-17Mar 30, 2022
Strategic Collaboration
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Bayer
PR-M11-20-030Dec 10, 2020
Clinical Study
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
BioLineRx
PR-M08-18-NI-030Aug 08, 2018